Embedded Files
DelveInsight's "Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Analysis, 2025" delivers extensive intelligence on over 10 pharmaceutical firms and more than 10 investigational medications within the SYK Inhibitors development arena. The analysis encompasses profiles of SYK Inhibitor pipeline therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant pipeline products in this therapeutic area.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the SYK Inhibitor Treatment Landscape @ SYK Inhibitor Pipeline Outlook
Primary Highlights from the SYK Inhibitor Pipeline Analysis
Primary Highlights from the SYK Inhibitor Pipeline Analysis
On November 24, 2025, Cancer Research UK initiated the DETERMINE trial which will recruit adults, teenagers and children. If a drug is found to benefit a new patient group, the study team will work with the NHS and the Cancer Drugs Funds to see if these drugs can be available for patients in the future. This clinicaltrials.gov record refers to the Overall Trial Protocol (Master Screening Record), additional records will be added to clinicaltrials.gov for each treatment arm.
DelveInsight's SYK Inhibitor pipeline analysis reveals a dynamic field featuring more than 10 engaged entities advancing over 10 investigational treatments for SYK Inhibitor applications.
Major SYK Inhibitor pharmaceutical firms include Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences, among additional organizations.
Notable SYK Inhibitor Pipeline investigational medications include SKI-O-703, Entospletinib, among others.
Stay informed about the cutting-edge advancements in SYK Inhibitor treatments. Access updates and participate in the revolution @ SYK Inhibitor Clinical Trials Assessment
The SYK Inhibitors Pipeline Analysis delivers a therapeutic overview, pipeline landscape, and evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning the development of SYK Inhibitors.
SYK Inhibitors Background
SYK Inhibitors Background
SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells. Mammals also express a SYK homologue, ZAP70, which is mostly restricted to T- and NK-lineage cells. SYK-related kinases are also found in invertebrates.
SYK Inhibitor Investigational Drug Profiles
SYK Inhibitor Investigational Drug Profiles
Cevidoplenib dimesylate: Genosco
The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.
HMPL-523: Hutchison MediPharma
An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.
The SYK Inhibitor Pipeline Analysis Offers Insights Into
The SYK Inhibitor Pipeline Analysis Offers Insights Into
The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics targeting SYK Inhibitors, including cumulative therapies created by each organization.
It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for SYK Inhibitor applications.
SYK Inhibitor pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.
SYK Inhibitor investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.
Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the SYK Inhibitor market.
Discover more about SYK Inhibitor therapeutic opportunities in our groundbreaking SYK Inhibitor research and development initiatives @ SYK Inhibitor Unmet Needs
SYK Inhibitor Pharmaceutical Firms
SYK Inhibitor Pharmaceutical Firms
Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences, among additional organizations.
The Spleen Tyrosine Kinase (SYK) Inhibitors pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:
Oral Intravenous
Molecular Classification
Molecular Classification
SYK Inhibitor products are classified under various molecular categories including:
Monoclonal antibodies Small molecules
Product Category
Product Category
Stay informed about how we're transforming the future of SYK landscape @ SYK Inhibitor Market Drivers and Barriers, and Future Perspectives
Scope of the SYK Inhibitor Pipeline Analysis
Scope of the SYK Inhibitor Pipeline Analysis
Coverage: Global
SYK Inhibitor Pharmaceutical Firms: Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences, among additional organizations.
SYK Inhibitor Pipeline Investigational Treatments: SKI-O-703, Entospletinib, among others.
SYK Inhibitor Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination
SYK Inhibitor Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III
For a comprehensive overview of our latest research findings and future plans, access the complete details of SYK Inhibitor Pipeline on our website @ SYK Inhibitor Emerging Drugs and Companies
Table of Content
Table of Content
Introduction
Executive Summary
Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Spleen Tyrosine Kinase (SYK) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
Late Stage Products (Phase II/III)
TOP 1630: TopiVert
Mid Stage Products (Phase II)
Cevidoplenib: Genosco
PRT 2761: Portola Pharmaceuticals
Early Stage Products (Phase I/II)
Gusacitinib: Asana BioSciences
Early Stage Products (Phase I)
Mivavotinib: Takeda Oncology
Pre-clinical and Discovery Stage Products
Research programme: small molecule therapeutics: Genosco
Inactive Products
Comparative Analysis
Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
Appendix
About Us
About Us
DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.
Contact Us
Contact Us
Kanishk
Page updated
Google Sites
Report abuse